Cost-effectiveness and population outcomes of general population screening for hepatitis C. - Wikidata - wikimedia - TriplyDB

Cost-effectiveness and population outcomes of general population screening for hepatitis C.

Cost-effectiveness and population outcomes of general population screening for hepatitis C.

http://www.wikidata.org/entity/Q36115516

about

Chronic HCV infection: epidemiological and clinical relevance Cost-Effectiveness of HBV and HCV Screening Strategies--A Systematic Review of Existing Modelling Techniques The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis Chronic hepatitis C and liver fibrosis.Economic evaluation of screening programs for hepatitis C virus infection: evidence from literature Hepatitis C - Assessment to Treatment Trial (HepCATT) in primary care: study protocol for a cluster randomised controlled trial.Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies.Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review.The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.Impact of an Electronic Medical Record-Based System to Promote Human Immunodeficiency Virus/Hepatitis C Virus Screening in Public Hospital Primary Care Clinics Screening, detecting and enhancing the yield of previously undiagnosed hepatitis B and C in patients with acute medical admissions to hospital: a pilot project undertaken at the Vancouver General Hospital Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.Ending hepatitis C in the United States: the role of screening.Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.The changing burden of hepatitis C virus infection in the United States: model-based predictions.Screening for hepatitis C in average and high-risk populations of Qatar using rapid point-of-care testing Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C.Hepatitis C screening: getting it right.Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.Hepatitis C virus in Mexican Americans: a population-based study reveals relatively high prevalence and negative association with diabetes.Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations.Integrated screening for tuberculosis and HIV in tuberculosis contact investigations: lessons learned in North Carolina.Potential market size and impact of hepatitis C treatment in low- and middle-income countries.Screening for hepatitis B and C in first-generation Egyptian migrants living in the Netherlands.Cost-Effectiveness of the Hepatitis C Self-Management Program.Population-level intervention and information collection in dynamic healthcare policy.Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis.The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics.Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.Uptake of hepatitis C screening, characteristics of patients tested, and intervention costs in the BEST-C study.Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease.Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway.Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease.Screening for hepatitis C virus infection.All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses.

P2860

Q21261812-FAEDEC12-AFBA-496A-9653-841A7BB10E3A Q26774500-23B4BCCB-6095-42E6-83E2-481A10003BE3 Q26777560-F5978209-6DCA-4590-9A43-1714CA45F659 Q26825671-2F9DF8D1-CCC0-4099-BB87-596F51819845 Q26998567-E9B814F2-74F1-4EF8-AD20-AB25C22E44E4 Q27332215-EA814A96-1FB8-4379-AEA9-C6B6F3E6BCB5 Q28488762-0F9A0A33-D5D3-4210-B4B8-A98BA792C095 Q28681550-6C0247B2-F6D1-4B93-8AA1-C6702DB91565 Q33572715-6FAC9E61-C38A-4CD1-8651-AB52C9E90569 Q33590896-E6A16D76-C74B-4CB6-BDCA-B860FE9A9E43 Q33710740-27548DCD-00D6-41CB-8FA4-5E6734004644 Q33745336-E3289364-BF4E-49D2-B819-0C630719D4B7 Q33810973-7AC8B89A-AA4B-4907-AD99-9F18D3C878B4 Q33831652-E672A531-C12A-465D-868F-8E466EF44773 Q33862919-C8C7AE46-2A94-403B-B78D-EEF5856D2F1C Q34677180-3C9134E8-81E7-4D3C-B48C-720A31B6CA94 Q35168083-86AF18B9-6773-475B-ADD0-E5555FE0CA66 Q35926098-148298E8-81B3-4D51-9740-2C16E9E3D8B5 Q36242517-CB707003-ADE5-4CC6-BB6B-EB4D0E927318 Q36479439-75D01EBA-61E6-46CC-AADA-5C9EBD5144FC Q36575211-9E5D7344-75BC-41FD-B8AC-2109C56FDDA7 Q37027342-78B4F24D-8EEF-4A66-A278-C7F3B0981320 Q37237054-B88FF709-20BF-4035-84F8-A61C599CB6EC Q37251861-914B07D2-F713-4F22-A68C-674303D58160 Q37391637-53287176-C76C-4A93-83D5-31E7F8065C02 Q38902281-3D5E33EF-726F-47B8-A4E0-6768C961B811 Q39634561-3C5B393F-69D8-40A1-9AAF-1B0908CD18D0 Q39749160-AA957744-EB8C-4F86-B4C4-FA72CE52445D Q40049914-ECDF7E81-AA65-4040-9E29-E6EDB1067906 Q40159136-F1F6D7ED-5ED0-47BC-A8FE-4FD3F28D3A00 Q40168920-A836548F-D1B3-455A-92A2-C69885BB2AE5 Q40291907-1112D940-BCF4-4CEA-B000-1E534D7C507D Q40524477-4D94BCD2-882E-4D0B-9AD9-81666B23B22E Q40576603-E4A514C4-0ACE-4C33-AF71-6D88CAC124B2 Q41207230-C9BE5C17-3A72-4D2A-89B3-C1E3A413A400 Q41486392-D80C843C-C5D1-4B36-ACCE-71BD447B5B68 Q41711879-340B8BAB-00D5-44D9-BA59-9F421925CF15 Q42048758-021EC0F5-DAAC-4416-AA90-2FE16C40A957 Q42155317-70FB8217-4F59-41A9-A5C0-2CB775A2B561 Q42251203-80D8DD1C-258A-4A55-AABE-9C65797F1C6A

P2860

Cost-effectiveness and population outcomes of general population screening for hepatitis C.

http://www.wikidata.org/entity/Q36115516

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Cost-effectiveness and populat ...... ion screening for hepatitis C.

@ast

Cost-effectiveness and populat ...... ion screening for hepatitis C.

@en

type

label

Cost-effectiveness and populat ...... ion screening for hepatitis C.

@ast

Cost-effectiveness and populat ...... ion screening for hepatitis C.

@en

prefLabel

Cost-effectiveness and populat ...... ion screening for hepatitis C.

@ast

Cost-effectiveness and populat ...... ion screening for hepatitis C.

@en

P1433

Q36115516-5A42C3E1-1B08-4E32-B3DE-8F73AFDFFC21

P1476

Q36115516-7B6B169E-C732-41F3-B46C-71ED4A6D4D2D

P2093

Q36115516-9EF95D0A-5B0B-445B-B53A-5C7FEFD3011B

Q36115516-B811A9E8-4665-404B-9123-1A2D421DE312

Q36115516-BA99DE62-D089-49CC-B2DB-07243E01E6EA

Q36115516-CB2DB204-1D55-4E2D-B1CD-C1B853FDD385

P2860

Q36115516-031634E0-EB2F-47EF-98ED-D6D566D3DA5B

Q36115516-065D3A47-35CC-4ACD-8A77-79EC464124D5

Q36115516-0BBCC455-1E28-4784-98EB-24132AEF9C6E

Q36115516-0D3F0D28-299F-4D3C-9ACF-FFD9C3707CF7

Q36115516-1D1637CB-04BA-4E07-AF70-9AA127632260

Q36115516-1D9093AC-DB8A-4C22-B49D-396F7B2DA2FB

Q36115516-21E6A432-EE8C-449C-83F9-B1622B020365

Q36115516-27865CD2-2A23-49BD-B9B2-25DDE9C7AA33

Q36115516-2ED1912D-BE4E-4573-88FE-A7D0524D361B

Q36115516-2EDB02DB-5384-4CC9-897B-E130676EA7D1

P304

Q36115516-62116781-A8BC-4977-81AB-9317B75DB4D9

P31

Q36115516-42F2B27A-646F-400C-9B73-1A10FCADEAE5

P356

Q36115516-14B5F540-EE55-4583-BEE6-EBA4C9D044DC

P407

Q36115516-E86E783E-589B-45AD-8494-89FE0B9B7C0E

P433

Q36115516-7964D331-15F2-49C9-92FD-37F6F78AE3BE

P478

Q36115516-0B9AB005-288C-42BC-BA86-063E2F5F4F80

P577

Q36115516-0B626814-6034-4A8D-9127-1B001A5FCACB

P5875

Q36115516-1C1BD247-BE84-4B0C-9D26-37C97D0B97C0

P698

Q36115516-597B360B-E5BC-4B7B-94DE-2082844DF5CC

P932

Q36115516-6ACE4D1F-73CA-468B-9F3F-6E95268AA63B

P356

P1433

Clinical Infectious Diseases

P1476

Cost-effectiveness and populat ...... ion screening for hepatitis C.

@en

P2093

John D Scott

http://www.w3.org/2001/XMLSchema#string

Matthew R Golden

http://www.w3.org/2001/XMLSchema#string

Phillip O Coffin

http://www.w3.org/2001/XMLSchema#string

Sean D Sullivan

http://www.w3.org/2001/XMLSchema#string

P2860

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

Comparison of Second- and Third-Generation Enzyme Immunoassays for Detecting Antibodies to Hepatitis C Virus

Self-reported hepatitis C virus antibody status and risk behavior in young injectors

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Diagnosis, management, and treatment of hepatitis C: an update

Evolving epidemiology of hepatitis C virus

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers.

The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.

P304

1259-1271

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIS011

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221697874

http://www.w3.org/2001/XMLSchema#string

P698

22412061

http://www.w3.org/2001/XMLSchema#string

P932

3404694

http://www.w3.org/2001/XMLSchema#string